Suppr超能文献

通过对细胞因子受体进行自上而下的基序工程改造,指导造血干细胞的体外扩增。

Top-down motif engineering of a cytokine receptor for directing ex vivo expansion of hematopoietic stem cells.

机构信息

Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.

出版信息

J Biotechnol. 2013 Dec;168(4):659-65. doi: 10.1016/j.jbiotec.2013.09.012. Epub 2013 Sep 23.

Abstract

The technique to expand hematopoietic stem cells (HSCs) ex vivo is eagerly anticipated to secure an enough amount of HSCs for clinical applications. Previously we developed a scFv-thrombopoietin receptor (c-Mpl) chimera, named S-Mpl, which can transduce a proliferation signal in HSCs in response to a cognate antigen. However, a remaining concern of the S-Mpl chimera may be the magnitude of the cellular expansion level driven by this molecule, which was significantly less than that mediated by endogenous wild-type c-Mpl. In this study, we engineered a tyrosine motif located in the intracellular domain of S-Mpl based on a top-down approach in order to change the signaling properties of the chimera. The truncated mutant (trunc.) and an amino-acid substitution mutant (Q to L) of S-Mpl were constructed to investigate the ability of these mutants to expand HSCs. The result showed that the truncated and Q to L mutants gave higher and considerably lower number of the cells than unmodified S-Mpl, respectively. The proliferation level through the truncated mutant was even higher than that of non-transduced HSCs with the stimulation of a native cytokine, thrombopoietin. Moreover, we analyzed the signaling properties of the S-Mpl mutants in detail using a pro-B cell line Ba/F3. The data indicated that the STAT3 and STAT5 activation levels through the truncated mutant increased, whereas activation of the Q to L mutant was inhibited by a negative regulator of intracellular signaling, SHP-1. This is the first demonstration that a non-natural artificial mutant of a cytokine receptor is effective for ex vivo expansion of hematopoietic cells compared with a native cytokine receptor.

摘要

体外扩增造血干细胞(HSCs)的技术备受期待,以确保有足够数量的 HSCs 用于临床应用。此前,我们开发了一种 scFv-血小板生成素受体(c-Mpl)嵌合体,命名为 S-Mpl,它可以在 HSCs 中传递增殖信号,以响应同源抗原。然而,S-Mpl 嵌合体的一个遗留问题可能是该分子驱动的细胞扩增水平的幅度,这显著小于内源性野生型 c-Mpl 介导的水平。在这项研究中,我们基于自上而下的方法对位于 S-Mpl 细胞内结构域中的酪氨酸基序进行了工程改造,以改变嵌合体的信号转导特性。构建了 S-Mpl 的截断突变体(trunc.)和氨基酸取代突变体(Q 到 L),以研究这些突变体扩增 HSCs 的能力。结果表明,截断和 Q 到 L 突变体分别比未修饰的 S-Mpl 产生更多和显著更少的细胞。通过截断突变体的增殖水平甚至高于未转导的 HSCs 在天然细胞因子血小板生成素刺激下的增殖水平。此外,我们使用前 B 细胞系 Ba/F3 详细分析了 S-Mpl 突变体的信号转导特性。数据表明,通过截断突变体的 STAT3 和 STAT5 激活水平增加,而 Q 到 L 突变体的激活被细胞内信号负调节剂 SHP-1 抑制。这是首次证明与天然细胞因子受体相比,细胞因子受体的非天然人工突变体可有效用于体外扩增造血细胞。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验